The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (Q84227123)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

multiple drug resistance

1 reference

1 reference

M P Smerdel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

K D Steffensen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Waldstrøm

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

I Brandslund

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Jakobsen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

14 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

118

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

167-171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Vascular endothelial growth factor as a target for anticancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

The biology of VEGF and its receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Circulating biomarkers of bevacizumab activity in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

A New Statistical Method for Haplotype Reconstruction from Population Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.018

10.1016/J.YGYNO.2010.03.018

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20471067%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference